Free Trial
NASDAQ:TERN

Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Terns Pharmaceuticals logo
$5.86 -0.19 (-3.14%)
(As of 05:40 PM ET)

About Terns Pharmaceuticals Stock (NASDAQ:TERN)

Key Stats

Today's Range
$5.78
$6.13
50-Day Range
$5.60
$7.67
52-Week Range
$4.32
$11.40
Volume
4.75 million shs
Average Volume
1.36 million shs
Market Capitalization
$497.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.30
Consensus Rating
Moderate Buy

Company Overview

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
84th Percentile Overall Score

TERN MarketRank™: 

Terns Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 170th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Terns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Terns Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Terns Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Terns Pharmaceuticals is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Terns Pharmaceuticals is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Terns Pharmaceuticals has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.67% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 35.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Terns Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Terns Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.67% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 35.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Terns Pharmaceuticals has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Terns Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for TERN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Terns Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $110,468.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    15.10% of the stock of Terns Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Terns Pharmaceuticals' insider trading history.
Receive TERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TERN Stock News Headlines

We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Terns Pharmaceuticals CEO & Director Acquires 423% More Stock
Terns Pharmaceuticals price target raised to $20 from $17 at Oppenheimer
See More Headlines

TERN Stock Analysis - Frequently Asked Questions

Terns Pharmaceuticals' stock was trading at $6.49 at the start of the year. Since then, TERN shares have decreased by 9.7% and is now trading at $5.86.
View the best growth stocks for 2024 here
.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.05.

Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO.

Terns Pharmaceuticals' top institutional investors include Point72 Asset Management L.P. (3.19%), Geode Capital Management LLC (1.42%), FMR LLC (1.67%) and State Street Corp (1.32%). Insiders that own company stock include Orbimed Advisors Llc, Hongbo Lu, Biosciences Fund V LP Lav, Vivo Opportunity, Llc, Mark J Vignola, Amy L Burroughs and Jill M Quigley.
View institutional ownership trends
.

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

Last Earnings
11/12/2024
Today
12/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TERN
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.30
High Stock Price Target
$26.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+205.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-90,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$4.13 per share

Miscellaneous

Free Float
72,113,000
Market Cap
$508.78 million
Optionable
Not Optionable
Beta
-0.36
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:TERN) was last updated on 12/20/2024 by MarketBeat.com Staff
From Our Partners